UBS Asset Management Americas Inc. reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 72.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 72,521 shares of the medical device company’s stock after selling 194,226 shares during the quarter. UBS Asset Management Americas Inc. owned 0.08% of DexCom worth $4,162,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in DXCM. Thompson Davis & CO. Inc. purchased a new stake in DexCom during the fourth quarter worth approximately $137,000. Zions Bancorporation grew its stake in DexCom by 36,222.2% during the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock worth $160,000 after buying an additional 3,260 shares during the period. Toronto Dominion Bank grew its stake in DexCom by 251.0% during the third quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock worth $178,000 after buying an additional 2,608 shares during the period. D.A. Davidson & CO. purchased a new stake in DexCom during the fourth quarter worth approximately $208,000. Finally, First Manhattan Co. purchased a new position in shares of DexCom in the fourth quarter valued at $223,000.
Several brokerages have recently weighed in on DXCM. Zacks Investment Research downgraded shares of DexCom from a “hold” rating to a “sell” rating in a research note on Friday, March 2nd. BidaskClub downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. Piper Jaffray Companies restated a “buy” rating on shares of DexCom in a research note on Monday. Canaccord Genuity upped their target price on shares of DexCom from $62.00 to $71.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Finally, Oppenheimer set a $67.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Wednesday, February 28th. Three analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $65.97.
Shares of DexCom, Inc. (DXCM) opened at $64.91 on Wednesday. The company has a debt-to-equity ratio of 0.78, a current ratio of 5.36 and a quick ratio of 5.04. DexCom, Inc. has a twelve month low of $42.62 and a twelve month high of $86.32.
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, February 27th. The medical device company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.07. The firm had revenue of $221.00 million for the quarter, compared to analysts’ expectations of $217.82 million. DexCom had a negative net margin of 6.99% and a negative return on equity of 13.99%. research analysts forecast that DexCom, Inc. will post -0.57 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “DexCom, Inc. (DXCM) Position Cut by UBS Asset Management Americas Inc.” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/03/14/dexcom-inc-dxcm-position-cut-by-ubs-asset-management-americas-inc.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.